# Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution

> **NCT04792034** · PHASE3 · RECRUITING · sponsor: **Noden Pharma** · enrollment: 40 (estimated)

## Conditions studied

- ENT Disorder
- Nasal Procedures
- Nasal Anesthesia
- Nasal Mucosa Surgery

## Interventions

- **DRUG:** Cocaine Hydrochloride Nasal Solution
- **DRUG:** Cocaine Hydrochloride Nasal Solution

## Key facts

- **NCT ID:** NCT04792034
- **Lead sponsor:** Noden Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-06
- **Primary completion:** 2027-12
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04792034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04792034, "Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04792034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*